Molecular Formula | C18H12Cl2N4O4S |
Molar Mass | 451.28 |
Density | 1.58±0.1 g/cm3(Predicted) |
Boling Point | 668.9±65.0 °C(Predicted) |
Solubility | DMSO: ≥ 35 mg/mL |
Appearance | Brown solid. |
pKa | 0.89±0.41(Predicted) |
Storage Condition | -20℃ |
In vitro study | 4 gi-1 disrupts the eIF4F complex and inhibits Cap-mediated translation in vitro. 4 gi-1 has pro-apoptotic activity in Jurkat cells, and can effectively inhibit cell growth in A549 lung cancer cells, and its IC50 value is about 6 μm. In human lung cancer cells, 4gi-1 increases TRAIL-induced apoptosis by inducing DR5 and down-regulating c-FLIP, separate inhibition of cap-dependent protein translation. In addition, in chronic lymphocytic carcinoma, 4gi-1 restores sensitivity to ABT-737 through cap-dependent and non-dependent mechanisms. 4 gi-1 disrupts the eIF4F complex and inhibits Cap-mediated translation in vitro. 4 gi-1 has pro-apoptotic activity in Jurkat cells, and can effectively inhibit cell growth in A549 lung cancer cells, and its IC50 value is about 6 μm. In human lung cancer cells, 4gi-1 increases TRAIL-induced apoptosis by inducing DR5 and down-regulating c-FLIP, separate inhibition of cap-dependent protein translation. In addition, in chronic lymphocytic carcinoma, 4gi-1 restores sensitivity to ABT-737 through cap-dependent and non-dependent mechanisms. |
In vivo study | 4EGI-1 (75 mg/kg, i.p.) inhibits breast cancer stem cells (CSC) tumor growth and tumorangiogenesis in vivo. 4EGI-1 (75 mg/kg, i.p.) shows inhibitory effect on the tumor volume and weight in mice bearing U87 cells. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.216 ml | 11.08 ml | 22.159 ml |
5 mM | 0.443 ml | 2.216 ml | 4.432 ml |
10 mM | 0.222 ml | 1.108 ml | 2.216 ml |
5 mM | 0.044 ml | 0.222 ml | 0.443 ml |